Table 4

Comparison of proportion of positive sentiment for efficacy among biological disease modifying anti-rheumatic drugs

Abatacept 86.04%Adalimumab 85.29%Certolizumab 83.08%Etanercept 87.06%Golimumab 86.27%Infliximab 84.94%Rituximab 84.64%Tocilizumab 87.24%Tofacitinib 81.21%
Abatacept 86.04%NADUPDUPDUPDUPDUPDUPDUPDUP
Adalimumab 85.29%0.75%NADUPDUPDUPDUPDUPDUPDUP
Certolizumab 83.08%2.96%2.21%NADUPDUPDUPDUPDUPDUP
Etanercept 87.06%1.02% *1.77% *3.98% NADUPDUPDUPDUPDUP
Golimumab 86.27%0.23%0.98%3.19%0.79%NADUPDUPDUPDUP
Infliximab 84.94%1.10%0.35%1.86% *2.12% 1.34%NADUPDUPDUP
Rituximab 84.64%1.40%0.65%1.56% *2.42% 1.63%0.30%NADUPDUP
Tocilizumab 87.24%1.20%1.95%4.16%0.18%0.97%2.30%2.60%NADUP
Tofacitinib 81.21% *4.83% *4.08% 1.87% *5.85% 5.06%3.73%3.43% *6.03% NA
  • *p<0.05.

  • DUP, duplicate value; NA, not applicable.